Summary

Overview
The Japan apheresis market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Apheresis is a process of removal of whole blood from a donor or a patient which is then centrifuged to separate the blood components such as platelets, plasma, red blood cells (RBCs), and white blood cells (WBCs). After the separation the desired component is retained and the rest is retransfused back to the donor. The principle of separation behind the apheresis is centrifugation, where the components get separated based on their density. Apheresis is performed for donated blood and also plays a vital role in several therapies such as the treatment of leukemia, sickle cell anemia, auto-immune disorders, and several neurological conditions.
Market Dynamics: Drivers
Rising initiatives by major market players in Japan
Several manufacturers who are leading in these technologies, also based in Japan have taken initiatives such as conducting educational sessions and offering hands-on training services across Japan. These initiatives aim at employing apheresis technology in manufacturing as well as clinical settings and are expected to boost the market growth in the forecast period.
For instance, on 25 May 2023, Terumo Blood and Cell Technologies (Terumo BCT) launched the first-ever training program on cell and blood collection technologies, especially apheresis. This training program aims to train participants on how to shorten, streamline, and standardize the cell collection process. This initiative will help to raise the adoption of apheresis technology by cell and gene therapy manufacturers.
One of the leading players in apheresis technology, Asahi Kasei Corporation. as a part of its R&D program has been offering training for therapeutic apheresis in its facility called the Apheresis Technology Square (the A-Square). This center provides hands-on training with the latest information on therapeutic apheresis to healthcare professionals all across Japan and the world.
Also, on October 22, 2023, a Japan-based company TAGCyx Biotechnologies announced the presentation of its novel developments in apheresis technology at the 44th Annual Meeting of the Japanese Society for Apheresis. The company has been working on the development of an apheresis column specific for preeclampsia using nucleic acid DNA aptamers. This column aims at filtering the specific molecules that are responsible for preeclampsia. The company is conducting animal studies using the mini-columns.
Restraints
Factors such as the risk of infection transmission and the shortage of blood donors are expected to restrain the market growth. For instance, on October 30, 2023, an article published in the Japan Times, stated that according to data from the Japanese Red Cross Society, the proportion of blood donors under 40 in Japan has decreased by 33% over the past ten years, which is concerning given the country's increasingly aging population. Also, if younger generations continue to donate less, there may eventually be a severe shortage of supplies since demand will exceed availability.
Segment Analysis
The Japan apheresis market is segmented based on product type, technology, end-users and region.
The membrane filtration in the technology segment accounted for approximately 43.5% of the Japan apheresis market share
Initially, the apheresis technology in Japan was adopted from the U.S. and is based on the centrifugation process. With the advent of technology, many major players who are specialized in manufacturing apheresis devices have come up with technologies that deviate from centrifugation. The apheresis technology that is quite popular in Japan currently is membrane filtration. The therapeutic apheresis in Japan is majorly based on this technique. The Japanese society even formed special guidelines to be followed during the procedure taking into consideration the membrane filtration technology. Moreover, the Japan-based companies that play a key role in the apheresis market offer products based on membrane filtration technology.
For instance, in December 2021, the guidelines released by the Japan Society of Apheresis differed from those of the United States and Europe. While apheresis in the United States and Europe is done using centrifugation, apheresis in Japan is based on the principle of membrane separation. The technological challenges in converting to the European and American recommendations for therapeutic apheresis led to the creation of the guidelines.
Competitive Landscape
The major players in the apheresis market include Asahi Kasei Medical Co., Ltd., SB-KAWASUMI LABORATORIES, INC., Terumo Corporation, KANEKA CORPORATION, Otsuka Medical Devices Co., Ltd., Nikkiso Co., Ltd., Haemonetics Corporation, and B. Braun SE among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the Japan apheresis market. Apart from vaccination, and diet modifications, extracorporeal apheresis has become one of the recommended practices for COVID-19 treatment. To tackle the cytokine rush, reduce inflammation, and decrease the risk of mortality, apheresis has been followed in many countries. During this period, the practice has been increased in Japan as well.
For instance, on May 12, 2022, according to an article published in the National Center for Biotechnology Information, during the COVID-19 pandemic, several majorly affected countries have incorporated extracorporeal apheresis in the treatment. The notable countries which have adopted this method include the U.S., Japan, Italy, and Russia.
Market Segmentation
By Product Type
• Devices
• Consumables & Accessories
By Technology
• Centrifugation
• Membrane Filtration
By Procedure
• Plasmapheresis
• Plateletpheresis
• Erythocytapheresis
• Leukapheresis
• Others
By Applications
• Donor Blood Apheresis
• Therapeutic Apheresis
• Blood Borne Disorders
• Auto-Immune Disorders
• Cardiovascular Disorders
• Neurological Disorders
• Others
By End Users
• Hospitals
• Blood Banks
• Clinics
• Others
Why Purchase the Report?
• To visualize the Japan apheresis market segmentation based on product type, technology, procedure, applications, end users as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of apheresis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The Japan apheresis market report would provide approximately 39 tables, 34 figures, and 187 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by Procedure
3.4. Snippet by Applications
3.5. Snippet by End Users
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising initiatives by major market players
4.1.1.2. Rising prevalence of chronic conditions
4.1.2. Restraints
4.1.2.1. Shortage of blood donors
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Devices*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Consumables & Accessories
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Centrifugation*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Membrane Filtration
9. By Procedure
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
9.1.2. Market Attractiveness Index, By Procedure
9.2. Plasmapheresis*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Plateletpheresis
9.4. Erythocytapheresis
9.5. Leukapheresis
9.6. Others
10. By Applications
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
10.1.2. Market Attractiveness Index, By Applications
10.2. Donor Blood Apheresis*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Therapeutic Apheresis
10.3.1. Blood Borne Disorders
10.3.2. Auto-Immune Disorders
10.3.3. Cardiovascular Disorders
10.3.4. Neurological Disorders
10.3.5. Others
11. By End Users
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
11.1.2. Market Attractiveness Index, By End Users
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Blood Banks
11.4. Clinics
11.5. Others
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Asahi Kasei Medical Co., Ltd.
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. SB-KAWASUMI LABORATORIES, INC.
13.3. Terumo Corporation
13.4. KANEKA CORPORATION
13.5. Otsuka Medical Devices Co., Ltd.
13.6. Nikkiso Co., Ltd.
13.7. Haemonetics Corporation
13.8. B. Braun SE
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us